What is the clinical evidence from this study?

Study design: Meta-Analysis. Population: Cryptogenic stroke (n=3740). Intervention: Device closure vs. Medical therapy (aspirin). Primary outcome: Recurrent stroke rate (HR 0.41, 95% CI 0.28-0.60, p=<0.001).

What question did this study set out to answer?

The aim is to explore the various underlying pathologies of ischemic stroke and assess how antithrombotic therapy can help prevent recurrence.

March 13, 2026Open Access

Diverse pathologies underlying ischemic stroke and prevention of recurrence: novel evidence on antithrombotic therapy

Q: What are the key findings of this study?

Device closure significantly reduced the annual recurrent stroke rate to 0.47% compared to 1.09% with medical therapy, with a hazard ratio of 0.41.

Q: What question did this study set out to answer?

The aim is to explore the various underlying pathologies of ischemic stroke and assess how antithrombotic therapy can help prevent recurrence.

Resultado clave

Device closure significantly reduced the annual recurrent stroke rate to 0.47% compared to 1.09% with medical therapy, with a hazard ratio of 0.41.

Puntos clave

The aim is to explore the various underlying pathologies of ischemic stroke and assess how antithrombotic therapy can help prevent recurrence.
Analyzed different pathologies associated with ischemic stroke
Reviewed antithrombotic therapy effectiveness
Examined risk factors related to stroke recurrence
Identified multiple pathologies contributing to ischemic stroke
Demonstrated that tailored antithrombotic therapies can reduce recurrence risk
Found a significant correlation between certain risk factors and stroke outcomes

Diseño del estudio

Tipo

Meta-Analysis (n=3,740)

Multicéntrico

Sí

PICO

Población

Cryptogenic stroke (n=3,740)

Intervención / comparador

Device closure vs Medical therapy (aspirin)

Resultado principal

Recurrent stroke rate — HR 0.41 (0.28-0.60), p=<0.001

Resultado numérico

Estimación del efecto: HR 0.41 (95% CI 0.28-0.60)

Tasa de eventos absoluta: 0.47% vs 1.09%

valor p: p=<0.001

Resumen

Me gusta

Guardar

Ver artículo completo

Me gusta

Guardar

Ver artículo completo

Cite This Study

Yuji Ueno (Mon,) conducted a meta-analysis in Cryptogenic stroke (n=3,740). Device closure vs. Medical therapy (aspirin) was evaluated on Recurrent stroke rate (HR 0.41, 95% CI 0.28-0.60, p=<0.001). Device closure significantly reduced the annual recurrent stroke rate to 0.47% compared to 1.09% with medical therapy, with a hazard ratio of 0.41.

synapsesocial.com/papers/69b3aaa802a1e69014ccb7fc https://doi.org/https://doi.org/10.2169/naika.114.408